Welsh AI Life Sciences Firm Antiverse Secures £7 Million Equity Investment
Cardiff-based artificial intelligence life sciences venture Antiverse has successfully closed a significant £7 million Series A equity funding round. This substantial investment has been jointly backed by the Development Bank of Wales and the Cardiff Capital Region's Innovation Investment Capital fund, marking a powerful vote of confidence in the region's burgeoning tech sector.
International Support and Strategic Backing
The funding round also attracted strong international support, with Prague-based venture capital firm Soulmates Ventures leading the cohort of overseas investors. This represents the third investment in Antiverse by the Development Bank of Wales since it first provided early-stage seed capital to the company in 2020, demonstrating a consistent commitment to the firm's growth trajectory.
Notably, this deal marks the sixth investment made by the Cardiff Capital Region through its £50 million Innovation Investment Capital fund, which is professionally managed by Capricorn Fund Managers. While the specific value contributions from both the development bank and the IIC fund remain undisclosed, this collaboration represents the first instance where both entities have participated in the same investment round for Antiverse.
Revolutionizing Antibody Drug Discovery
Antiverse operates at the cutting edge of pharmaceutical innovation by applying advanced generative AI and machine learning technologies to predict, design, and optimize antibody-based drugs. The company's proprietary platform dramatically reduces both the time and cost associated with traditional drug discovery methods, enabling pharmaceutical and biotechnology partners to accelerate the development of life-changing treatments for patients worldwide.
The company's technology already supports critical research programs across multiple therapeutic areas including oncology, immunology, and infectious diseases, positioning Antiverse firmly at the forefront of next-generation therapeutics development.
Job Creation and Growth Acceleration
The substantial funding injection will enable Antiverse to accelerate the development of new intellectual property while expanding its local team in Cardiff. The investment is expected to create five new high-skilled positions while safeguarding an additional 19 existing jobs, providing a significant boost to the regional economy and reinforcing Wales' position as a hub for technological innovation.
Leadership Perspectives on the Investment
Murat Tunaboylu, Antiverse's co-founder and chief executive, expressed enthusiasm about the funding round, stating: "This is a powerful endorsement of both our technology and our roots in Cardiff. This investment not only enables us to scale our platform, grow our team and deepen partnerships with pharma and biotech leaders worldwide, but also positions Antiverse strongly for our next phase of growth."
Kellie Beirne, chief executive of the Cardiff Capital Region, emphasized the strategic importance of supporting innovative companies like Antiverse: "Antiverse is a great example of the kind of cutting-edge innovation we want to see growing in our region. By combining AI with life sciences, the team is tackling some of the most important challenges in healthcare today."
Rhian Elston, Wales investment director for the Development Bank of Wales, highlighted the global potential of the investment: "Antiverse represents a compelling life sciences opportunity with the potential to build a business of genuine global scale. We're pleased to be working alongside Innovation Investment Capital to continue our support for this Welsh-based tech business."
The successful funding round represents a significant milestone for Antiverse as it strengthens its foundations at Series A, laying crucial groundwork for future Series B expansion and broader global market penetration of its revolutionary AI-powered drug discovery platform.
